October 21, 2024

Strike Energy (ASX: STX) has announced remarkable production testing results from its Erregulla Deep-1 (ED-1) gas well, solidifying its potential impact on the West Erregulla gas field development. The ED-1 well, the deepest onshore well ever drilled in Australia, demonstrated stabilized flow rates of 53 million standard cubic feet per day (mmscfd) and a notable […]

Nick Scali Limited (ASX:NCK) has reported strong financial performance for FY24, driven by a gross margin increase to 66% across its Australian and New Zealand operations. However, the company has issued a profit warning, highlighting increased freight costs expected to impact first-half results for FY25. Managing Director Anthony Scali confirmed the company’s global ambitions following

Hazer Group Limited (ASX:HZR) continues to make significant progress with its clean hydrogen production technology, as highlighted in its latest quarterly report for the period ending 30 September 2024. The company achieved a major milestone with over 360 hours of continuous operation of its Commercial Demonstration Plant (CDP), showcasing high reliability and methane conversion efficiency.

Synlait Milk Limited (ASX:SM1) has announced the resignation of CEO Grant Watson, who led the company through a challenging period of financial restructuring. His tenure saw Synlait reduce its debt through a $130 million shareholder loan and a $218 million equity raise. Synlait Chair George Adams praised Watson’s leadership, stating, “Grant has been instrumental in

PYC Therapeutics (ASX:PYC) has received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for its drug candidate VP-001, aimed at treating Retinitis Pigmentosa type 11 (RP11). This breakthrough therapy is currently undergoing multiple clinical trials, representing a significant step forward for patients affected by this childhood disease. The ODD status confers

Acusensus Limited (ASX:ACE) is set to trial its Behaviour Awareness Monitoring (BAM) system on Queensland roads by the end of 2024. This innovative system, designed to reduce dangerous driving behaviour, alerts drivers in real-time if they are using mobile phones or tailgating. The BAM system also rewards safe driving practices, enhancing community education around road

Race Oncology (ASX:RAC) has completed its Phase 1b/2 trial of bisantrene in combination with clofarabine and fludarabine for the treatment of relapsed or refractory acute myeloid leukaemia (AML). AML is a type of cancer that starts in the bone marrow and often moves into the blood. It is characterised by the rapid growth of abnormal